WebbPublic Company Founded 2011 Specialties Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib Locations Primary New... Webb26 jan. 2024 · This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2024 to its short form base...
Mamma knullas mot sin vilja noveller
Webb20 okt. 2024 · Sona Nanotech CEO, David Regan commented, “ This agreement marks Sona’s first commercial arrangement of its gold nanorods for an emerging ‘in-vivo’ … Webb26 jan. 2024 · Siva Therapeutics, Inc. is developing Targeted Hyperthermia Therapy™, a photothermal cancer therapy in preclinical development, which uses therapeutic heat to … hond ridgeback
Len Pagliaro, Siva Therapeutics - Targeted Hyperthermia
Webb23 mars 2024 · About Siva Therapeutics, Inc.Siva Therapeutics Inc is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by SivaRods™ gold nanorods in the tumor and re-emitted as heat. WebbCEO, Siva Therapeutics Len Pagliaro, PhD, has 21 years of experience with successful commercialization of biotechnology products, services, and licensing, following an academic career. He has managed R&D and business development teams, and brought product lines from concept through commercialization to acquisition. Webb31 okt. 2024 · Sona Nanotech Inc. completed the acquisition of Siva Therapeutics Inc. 03/23/2024 EDT Sona Nanotech Inc. (CNSX:SONA) entered into a binding agreement to acquire Siva Therapeutics Inc. for $8.7 million on January 26, 2024. hond richback